UBS O'Connor
Latest statistics and disclosures from UBS OCONNOR's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Halcon Res, INAP, Orexigen Therapeutics, and represent 100.00% of UBS OCONNOR's stock portfolio.
- Added to shares of these 3 stocks: Halcon Res (+$30.28M), INAP (+$18.60M), Orexigen Therapeutics.
- Started 3 new stock positions in Orexigen Therapeutics, INAP, Halcon Res.
- Reduced shares in these 6 stocks: , RAD (-$50.23M), ODP (-$39.27M), IM (-$36.87M), Media Gen (-$29.40M), ITC (-$24.59M).
- Sold out of its positions in ALR, IM, ITC, Media Gen, ODP, RAD.
- UBS OCONNOR was a net seller of stock by $222.96M.
- UBS OCONNOR has $48.89M in assets under management (AUM), dropping by -82.02%.
UBS OCONNOR portfolio companies for March 2017 quarter
| Company (Ticker) | Portfolio Weight | Share Count | Price | Last Trade |
|---|---|---|---|---|
| Halcon Res | 61.95 | 4.14M NEW | 7.32 | 0.00 |
| InterNAP Network Services (INAP) | 38.05 | 5.00M NEW | 3.72 | 3.40 |
| Orexigen Therapeutics | 0.00 | 33333 NEW | 0.00 | 0.00 |
Download CSV 
Past 13F-HR SEC Filings for UBS OCONNOR
- UBS OCONNOR 2016 Q1 amended filed May 12, 2017
- UBS OCONNOR 2016 Q2 amended filed May 12, 2017
- UBS OCONNOR 2016 Q3 amended filed May 12, 2017
- UBS OCONNOR 2016 Q4 amended filed May 12, 2017
- UBS OCONNOR 2017 Q1 filed May 12, 2017
- UBS OCONNOR 2015 Q4 amended filed Feb. 15, 2017
- UBS OCONNOR 2016 Q3 amended filed Feb. 15, 2017
- UBS OCONNOR 2016 Q2 amended filed Feb. 14, 2017
- UBS OCONNOR 2015 Q4 amended filed Feb. 14, 2017
- UBS OCONNOR 2016 Q4 filed Feb. 14, 2017
- UBS OCONNOR 2016 Q1 amended filed Feb. 14, 2017
- UBS OCONNOR 2015 Q4 amended filed Nov. 14, 2016
- UBS OCONNOR 2016 Q1 amended filed Nov. 14, 2016
- UBS OCONNOR 2016 Q2 amended filed Nov. 14, 2016
- UBS OCONNOR 2016 Q3 filed Nov. 14, 2016
- UBS OCONNOR 2015 Q3 amended filed Nov. 14, 2016
- UBS OCONNOR 2016 Q2 amended filed Oct. 6, 2016
- UBS OCONNOR 2016 Q1 amended filed Oct. 6, 2016
- UBS OCONNOR 2015 Q4 amended filed Oct. 6, 2016